Cardiovascular risk factors and frontotemporal dementia: a case–control study

Translational Neurodegeneration

Edgardo Cristiano³  Enrique Soriano¹  Cristina Elizondo¹  María C Fernandez²  Juan I Rojas³  Nuria Cámpora²  Angel Golimstok² 

[1] Epidemiology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina;Cognitive and Behavior Unit, Department of Neurology, Hospital Italiano de Buenos Aires, Perón 4272, 1411 Buenos Aires, Argentina;Department of Neurology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

关键词: DM;    DBT;    Diabetes;    FTD;    Dementia;    Frontotemporal dementia;    Cardiovascular risk factors;   

Others  :  834352
DOI  :  10.1186/2047-9158-3-13

 received in 2014-03-21, accepted in 2014-06-13,  发布年份 2014

【 摘 要 】

Cardiovascular risk factors (CRF) were widely described as related to dementia. There are very few studies regarding this association in FTD. The objective of the study was to compare the frequency of CRF in our population with FTD and controls. 100 consecutive subjects with FTD diagnosis according to Lund-Manchester clinical criteria and 200 controls matched by age and sex were included between January 2003 to February 2007 at the Cognitive and Behavior Unit of Hospital Italiano de Buenos Aires. Clinical evaluation, laboratory tests, brain images (CT/MRI), neuropsychological and neuropsychiatric assessment were performed. Multiple regression analysis was performed to analyze the association in CRF between FTD patients vs. controls. The mean age in FTD was 69.7 ± 0.9 vs. 70.1 ± 0.8 in controls (p 0.12). No difference in gender was observed between cases and controls. No differences were identified between patients and controls regarding hypertension (HTA) (65% vs. 67,3% p 0.44); dyslipidemia (57% vs. 54.7% p 0.74); obesity (39% vs. 27.6% p 0.14) and hypothyroidism (26% vs. 17.1% p 0.1). A significant difference was observed for Diabetes Mellitus (39% vs. 22.6% p 0.001). In our population, Diabetes Mellitus was associated as an independent risk factor for FTD. To our knowledge this is the first report in which CRF were evaluated prospectively in FTD patients. More studies are needed to confirm this finding in larger populations.

【 授权许可】

   
2014 Golimstok et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]The Lund and Manchester Groups: Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry 1994, 57(4):416-418.
• [2]McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ, Pick’s D, Work Group on Frontotemporal: Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick’s Disease. Arch Neurol 2001, 58(11):1803-1809.
• [3]Bird T, Knopman D, VanSwieten J, Rosso S, Feldman H, Tanabe H, Graff-Raford N, Geschwind D, Verpillat P, Hutton M: Epidemiology and genetics of frontotemporal dementia/Pick’s disease. Ann Neurol 2003, 54(Suppl 5):S29-S31. doi:10.1002/ana.10572
• [4]Feldman H, Levy AR, Hsiung GY, Peters KR, Donald A, Black SE, Bouchard RW, Gauthier SG, Guzman DA, Hogan DB, Kertesz A, Rockwood K, Group AS: A Canadian cohort study of cognitive impairment and related dementias (ACCORD): study methods and baseline results. Neuroepidemiology 2003, 22(5):265-274. doi:71189
• [5]Rohrer JD, Guerreiro R, Vandrovcova J, Uphill J, Reiman D, Beck J, Isaacs AM, Authier A, Ferrari R, Fox NC, Mackenzie IR, Warren JD, de Silva R, Holton J, Revesz T, Hardy J, Mead S, Rossor MN: The heritability and genetics of frontotemporal lobar degeneration. Neurology 2009, 73(18):1451-1456. doi:10.1212/WNL.0b013e3181bf997a
• [6]Seelaar H, Kamphorst W, Rosso SM, Azmani A, Masdjedi R, de Koning I, Maat-Kievit JA, Anar B, Donker Kaat L, Breedveld GJ, Dooijes D, Rozemuller JM, Bronner IF, Rizzu P, van Swieten JC: Distinct genetic forms of frontotemporal dementia. Neurology 2008, 71(16):1220-1226. doi:10.1212/01.wnl.0000319702.37497.72
• [7]Rohrer JD, Warren JD: Phenotypic signatures of genetic frontotemporal dementia. Curr Opin Neurol 2011, 24(6):542-549. doi:10.1097/WCO.0b013e32834cd442
• [8]Chow TW, Miller BL, Hayashi VN, Geschwind DH: Inheritance of frontotemporal dementia. Arch Neurol 1999, 56(7):817-822.
• [9]Hodges JR, Mitchell J, Dawson K, Spillantini MG, Xuereb JH, McMonagle P, Nestor PJ, Patterson K: Semantic dementia: demography, familial factors and survival in a consecutive series of 100 cases. Brain 2010, 133(Pt 1):300-306. doi:10.1093/brain/awp248
• [10]Sharp SI, Aarsland D, Day S, Sonnesyn H, Alzheimer’s Society Vascular Dementia Systematic Review G, Ballard C: Hypertension is a potential risk factor for vascular dementia: systematic review. Int J Geriatr Psychiatry 2011, 26(7):661-669. doi:10.1002/gps.2572
• [11]Anstey KJ, Cherbuin N, Budge M, Young J: Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies. Obes Rev 2011, 12(5):e426-e437. doi:10.1111/j.1467-789X.2010.00825.x
• [12]Lu FP, Lin KP, Kuo HK: Diabetes and the risk of multi-system aging phenotypes: a systematic review and meta-analysis. PLoS One 2009, 4(1):e4144. doi:10.1371/journal.pone.0004144
• [13]Peters R, Poulter R, Warner J, Beckett N, Burch L, Bulpitt C: Smoking, dementia and cognitive decline in the elderly, a systematic review. BMC Geriatr 2008, 8:36. doi:10.1186/1471-2318-8-36
• [14]Anstey KJ, Lipnicki DM, Low LF: Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry 2008, 16(5):343-354. doi:10.1097/JGP.0b013e31816b72d4
• [15]Frigerio R, Fujishiro H, Maraganore DM, Klos KJ, DelleDonne A, Heckman MG, Crook JE, Josephs KA, Parisi JE, Boeve BF, Dickson DW, Ahlskog JE: Comparison of risk factor profiles in incidental Lewy body disease and Parkinson disease. Arch Neurol 2009, 66(9):1114-1119. doi:P10.1001/archneurol.2009.170
• [16]Boot BP, Orr CF, Ahlskog JE, Ferman TJ, Roberts R, Pankratz VS, Dickson DW, Parisi J, Aakre JA, Geda YE, Knopman DS, Petersen RC, Boeve BF: Risk factors for dementia with Lewy bodies: a case–control study. Neurology 2013, 81(9):833-840. doi:10.1212/WNL.0b013e3182a2cbd1
• [17]Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF: Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998, 51(6):1546-1554.
• [18]Rusanen M, Rovio S, Ngandu T, Nissinen A, Tuomilehto J, Soininen H, Kivipelto M: Midlife smoking, apolipoprotein E and risk of dementia and Alzheimer’s disease: a population-based cardiovascular risk factors, aging and dementia study. Dement Geriatr Cogn Disord 2010, 30(3):277-284. doi:10.1159/000320484
• [19]Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM: Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999, 53(9):1937-1942.
• [20]Sandoval CM: Importancia global y local de la diabetes mellitus tipo 2. Rev Hosp Clín Univ Chile 2012, 23:185-190.
• [21]Rosso SM, Landweer EJ, Houterman M, Donker Kaat L, van Duijn CM, van Swieten JC: Medical and environmental risk factors for sporadic frontotemporal dementia: a retrospective case–control study. J Neurol Neurosurg Psychiatry 2003, 74(11):1574-1576.
• [22]Gregg EW, Yaffe K, Cauley JA, Rolka DB, Blackwell TL, Narayan KM, Cummings SR: Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group. Arch Intern Med 2000, 160(2):174-180.
• [23]Benedict C, Brooks SJ, Kullberg J, Burgos J, Kempton MJ, Nordenskjold R, Nylander R, Kilander L, Craft S, Larsson EM, Johansson L, Ahlstrom H, Lind L, Schioth HB: Impaired insulin sensitivity as indexed by the HOMA score is associated with deficits in verbal fluency and temporal lobe gray matter volume in the elderly. Diabetes Care 2012, 35(3):488-494. doi:10.2337/dc11-2075
• [24]Ahtiluoto S, Polvikoski T, Peltonen M, Solomon A, Tuomilehto J, Winblad B, Sulkava R, Kivipelto M: Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology 2010, 75(13):1195-1202. doi:10.1212/WNL.0b013e3181f4d7f8
• [25]Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM: Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease–is this type 3 diabetes? J Alzheimers Dis 2005, 7(1):63-80.
• [26]Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM: Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer’s disease: link to brain reductions in acetylcholine. J Alzheimers Dis 2005, 8(3):247-268.
• [27]Schubert M, Brazil DP, Burks DJ, Kushner JA, Ye J, Flint CL, Farhang-Fallah J, Dikkes P, Warot XM, Rio C, Corfas G, White MF: Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci 2003, 23(18):7084-7092. doi:23/18/7084
• [28]Schubert M, Gautam D, Surjo D, Ueki K, Baudler S, Schubert D, Kondo T, Alber J, Galldiks N, Kustermann E, Arndt S, Jacobs AH, Krone W, Kahn CR, Bruning JC: Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci U S A 2004, 101(9):3100-3105. doi:10.1073/pnas.0308724101
• [29]Cukierman T, Gerstein HC, Williamson JD: Cognitive decline and dementia in diabetes–systematic overview of prospective observational studies. Diabetologia 2005, 48(12):2460-2469. doi:10.1007/s00125-005-0023-4
• [30]Snowden JS: Semantic dysfunction in frontotemporal lobar degeneration. Dement Geriatr Cogn Disord 1999, 10(Suppl 1):33-36. doi:51209
• [31]Hillis AE, Oh S, Ken L: Deterioration of naming nouns versus verbs in primary progressive aphasia. Ann Neurol 2004, 55(2):268-275. doi:10.1002/ana.10812
• [32]Lee CC, Kuo YM, Huang CC, Hsu KS: Insulin rescues amyloid beta-induced impairment of hippocampal long-term potentiation. Neurobiol Aging 2009, 30(3):377-387. doi:10.1016/j.neurobiolaging.2007.06.014
• [33]Figlewicz DP, Brot MD, McCall AL, Szot P: Diabetes causes differential changes in CNS noradrenergic and dopaminergic neurons in the rat: a molecular study. Brain Res 1996, 736(1–2):54-60.
• [34]Chan O, Chan S, Inouye K, Vranic M, Matthews SG: Molecular regulation of the hypothalamo-pituitary-adrenal axis in streptozotocin-induced diabetes: effects of insulin treatment. Endocrinology 2001, 142(11):4872-4879.
• [35]Havrankova J, Roth J, Brownstein M: Insulin receptors are widely distributed in the central nervous system of the rat. Nature 1978, 272(5656):827-829.
• [36]Baker LD, Cross DJ, Minoshima S, Belongia D, Watson GS, Craft S: Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol 2011, 68(1):51-57. doi:10.1001/archneurol.2010.225
• [37]Li XH, Lv BL, Xie JZ, Liu J, Zhou XW, Wang JZ: AGEs induce Alzheimer-like tau pathology and memory deficit via RAGE-mediated GSK-3 activation. Neurobiol Aging 2012, 33(7):1400-1410. doi:10.1016/j.neurobiolaging.2011.02.003
• [38]Chun W, Johnson GV: The role of tau phosphorylation and cleavage in neuronal cell death. Front Biosci 2007, 12:733-756.
• [39]Cohen P: The twentieth century struggle to decipher insulin signalling. Nat Rev Mol Cell Biol 2006, 7(11):867-873. doi:10.1038/nrm2043
• [40]Cohen P, Frame S: The renaissance of GSK3. Nat Rev Mol Cell Biol 2001, 2(10):769-776. doi:10.1038/35096075
• [41]Castillo-Quan JI, Barrera-Buenfil DJ, Perez-Osorio JM, Alvarez-Cervera FJ: Depression and diabetes: from epidemiology to neurobiology. Rev Neurol 2010, 51(6):347-359.
• [42]Chen Z, Li L, Sun J, Ma L: Mapping the brain in type II diabetes: Voxel-based morphometry using DARTEL. Eur J Radiol 2012, 81(8):1870-1876. doi:10.1016/j.ejrad.2011.04.025
• [43]Kumar A, Haroon E, Darwin C, Pham D, Ajilore O, Rodriguez G, Mintz J: Gray matter prefrontal changes in type 2 diabetes detected using MRI. J Magn Reson Imaging 2008, 27(1):14-19. doi:10.1002/jmri.21224
• [44]Womack KB, Diaz-Arrastia R, Aizenstein HJ, Arnold SE, Barbas NR, Boeve BF, Clark CM, DeCarli CS, Jagust WJ, Leverenz JB, Peskind ER, Turner RS, Zamrini EY, Heidebrink JL, Burke JR, DeKosky ST, Farlow MR, Gabel MJ, Higdon R, Kawas CH, Koeppe RA, Lipton AM, Foster NL: Temporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errors. Arch Neurol 2011, 68(3):329-337. doi:10.1001/archneurol.2010.295
• [45]Yau PL, Javier DC, Ryan CM, Tsui WH, Ardekani BA, Ten S, Convit A: Preliminary evidence for brain complications in obese adolescents with type 2 diabetes mellitus. Diabetologia 2010, 53(11):2298-2306. doi:10.1007/s00125-010-1857-y
• [46]Gunstad J, Paul RH, Cohen RA, Tate DF, Spitznagel MB, Grieve S, Gordon E: Relationship between body mass index and brain volume in healthy adults. Int J Neurosci 2008, 118(11):1582-1593. doi:10.1080/00207450701392282
• [47]Gunstad J, Paul RH, Cohen RA, Tate DF, Gordon E: Obesity is associated with memory deficits in young and middle-aged adults. Eat Weight Disord 2006, 11(1):e15-e19.
• [48]Whitmer RA, Gunderson EP, Quesenberry CP Jr, Zhou J, Yaffe K: Body mass index in midlife and risk of Alzheimer disease and vascular dementia. Curr Alzheimer Res 2007, 4(2):103-109.
• [49]Ott A, Slooter AJ, Hofman A, van Harskamp F, Witteman JC, Van Broeckhoven C, van Duijn CM, Breteler MM: Smoking and risk of dementia and Alzheimer’s disease in a population-based cohort study: the Rotterdam Study. Lancet 1998, 351(9119):1840-1843.
• [50]Aniello F, Couchie D, Bridoux AM, Gripois D, Nunez J: Splicing of juvenile and adult tau mRNA variants is regulated by thyroid hormone. Proc Natl Acad Sci U S A 1991, 88(9):4035-4039.
• [51]Faldt R, Passant U, Nilsson K, Wattmo C, Gustafson L: Prevalence of thyroid hormone abnormalities in elderly patients with symptoms of organic brain disease. Aging 1996, 8(5):347-353.
• [52]Kipen E, Helme RD, Wark JD, Flicker L: Bone density, vitamin D nutrition, and parathyroid hormone levels in women with dementia. J Am Geriatr Soc 1995, 43(10):1088-1091.